Monitoring Polymorphic Phase Transitions in Flufenamic Acid Amorphous Solid Dispersions Using Hyphenated X-ray Diffraction–Differential Scanning Calorimetry

Flufenamic acid (FFA) is a highly polymorphic drug molecule with nine crystal structures reported in the Cambridge Structural Database. This study explores the use of synchrotron X-ray powder diffraction combined with differential scanning calorimetry to study crystallization and polymorphic phase transitions upon heating FFA–polymer amorphous solid dispersions (ASDs). Ethyl cellulose (EC, 4 cp) and hydroxypropylmethylcellulose (HPMC) grades with different viscosities and substitution patterns were used to prepare dispersions with FFA at 5:1, 2:1, 1:1, and 1:5 w/w drug/polymer ratios by quench cooling. We employed a 6 cp HPMC 2910 material and two HPMC 2208 samples at 4000 and 100 000 cp. Hyphenated X-ray diffraction (XRD)–differential scanning calorimetry (DSC) studies show that the 6 and 100 000 cp HPMCs and 4 cp EC polymers can stabilize FFA form IV by inhibiting the transition to form I during heating. It appears that the polymers stabilize FFA in both amorphous and metastable forms via a combination of intermolecular interactions and viscosity effects. Increasing the polymer content of the ASD also inhibits polymorphic transitions, with drug/polymer ratios of 1:5 w/w resulting in FFA remaining amorphous during heating. The comparison of FFA ASDs prepared with different samples of HPMCs and ECs suggests that the chemical substitution of the polymer (HPMC 2208 has 19–24% methoxy groups and 4–12% hydroxypropyl groups, while HPMC 2910 has 28–30% methoxy groups and 7–12% hydroxypropyl groups) plays a more significant role in directing polymorphic transitions than the viscosity. A previously unreported polymorph of FFA was also noted during heating but its structure could not be determined.

[1]  Gareth R. Williams,et al.  Olanzapine Form IV: Discovery of a New Polymorphic Form Enabled by Computed Crystal Energy Landscapes , 2019, Crystal Growth & Design.

[2]  Gareth R. Williams,et al.  Polymorphic Phase Transitions in Carbamazepine and 10,11‐Dihydrocarbamazepine , 2018, Chemistry.

[3]  S. Price,et al.  Successful Computationally Directed Templating of Metastable Pharmaceutical Polymorphs , 2018, Crystal Growth & Design.

[4]  A. Alshetaili,et al.  Influence of the microwave technology on solid dispersions of mefenamic acid and flufenamic acid , 2017, PloS one.

[5]  Harsh Chauhan,et al.  Investigation and correlation of drug polymer miscibility and molecular interactions by various approaches for the preparation of amorphous solid dispersions. , 2015, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[6]  T. Korter,et al.  Conformational origins of polymorphism in two forms of flufenamic acid , 2014 .

[7]  M. Maniruzzaman,et al.  Drug-polymer intermolecular interactions in hot-melt extruded solid dispersions. , 2013, International journal of pharmaceutics.

[8]  Lynne S Taylor,et al.  Crystallization of amorphous solid dispersions of resveratrol during preparation and storage-Impact of different polymers. , 2013, Journal of pharmaceutical sciences.

[9]  B. Chowdhry,et al.  Raman and IR spectroscopic studies of fenamates--conformational differences in polymorphs of flufenamic acid, mefenamic acid and tolfenamic acid. , 2012, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.

[10]  A. Matzger,et al.  Nonamorphism in flufenamic acid and a new record for a polymorphic compound with solved structures. , 2012, Journal of the American Chemical Society.

[11]  G. Mooter,et al.  The use of amorphous solid dispersions: A formulation strategy to overcome poor solubility and dissolution rate. , 2012, Drug discovery today. Technologies.

[12]  Lynne S Taylor,et al.  Evaluation of amorphous solid dispersion properties using thermal analysis techniques. , 2012, Advanced drug delivery reviews.

[13]  Simon Parsons,et al.  The TOPAS symbolic computation system , 2011, Powder Diffraction.

[14]  S. Gaisford,et al.  Characterisation of paracetamol form III with rapid-heating DSC. , 2010, Journal of pharmaceutical and biomedical analysis.

[15]  B. Sarmento,et al.  Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. , 2007, Drug discovery today.

[16]  W. Liebenberg,et al.  Thermal methods for evaluating polymorphic transitions in nifedipine , 2007 .